ClinicalTrials.gg
CompletedNCT00387725Updated Nov 21, 2014Results posted

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

A Phase 2 interventional study of rLP2086 and rLP2086 in Healthy, sponsored by Pfizer. Completed at 9 sites in Australia. Open to participants aged 8 Years to 14 Years. Per ClinicalTrials.gov, last updated 2014-11-21.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
8 Years to 14 Years
Sex
All
01

Study summary

Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents

02

Conditions studied

  • Healthy

Keywords

  • Adolescent
  • Meningococcal
  • Safety
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria

  • Aged 8 to 14 years at the time of enrollment.
  • Healthy male or female subjects
  • Negative urine pregnancy test for female subjects

Exclusion Criteria:

Exclusion Criteria

  • Prior vaccination with a meningococcal B vaccine
  • Prior meningococcal disease
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Group A

    20ug Experimental

    Biological: rLP2086

  • Experimental
    Group 2

    60ug Experimental

    Biological: rLP2086

  • Experimental
    Group 3

    200ug Experimental

    Biological: rLP2086

  • Active comparator
    Group 4

    Active comparator

    Biological: rLP2086

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2

    Time frame: 1 month after Dose 2

  2. Percentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3

    Time frame: 1 month after Dose 3

  3. Percentage of Participants With at Least One Adverse Event (AE)

    Time frame: Dose 1 up to 1 month after Dose 3

07

Results

Posted Nov 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
Started21164545
Completed20154343
Not completed1122
Withdrew: Adverse event0001
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject1010
Withdrew: Parent/legal guardian request0011

Outcome measures

PrimaryPercentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2
Time frame:
1 month after Dose 2
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2
percentage of participantsTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
PMB1745 (N=19, 15, 44, 42)0.0 (0.0 to 17.6)33.3 (11.8 to 61.6)63.6 (47.8 to 77.6)83.3 (68.6 to 93.0)
PMB17 (N=18, 16, 44, 42)0.0 (0.0 to 18.5)18.8 (4.0 to 45.6)52.3 (36.7 to 67.5)61.9 (45.6 to 76.4)
PrimaryPercentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3
Time frame:
1 month after Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3
percentage of participantsTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
PMB1745 (N=19, 16, 41, 43)0.0 (0.0 to 17.6)68.8 (41.3 to 89.0)70.7 (54.5 to 83.9)90.7 (77.9 to 97.4)
PMB17 (N=18, 16, 41, 43)0.0 (0.0 to 18.5)87.5 (61.7 to 98.4)82.9 (67.9 to 92.8)95.3 (84.2 to 99.4)
PrimaryPercentage of Participants With at Least One Adverse Event (AE)
Time frame:
Dose 1 up to 1 month after Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event (AE)
percentage of participantsTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
Percentage of Participants With at Least One Adverse Event (AE)90.593.893.397.8

Adverse events

Collected over Dose 1 up to 1 month after Dose 3. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Twinrix—0/21 (0%)19/21 (90.5%)
Initial Formulation rLP2086 20 mcg—2/16 (12.5%)15/16 (93.8%)
Initial Formulation rLP2086 60 mcg—3/45 (6.7%)42/45 (93.3%)
Initial Formulation rLP2086 200 mcg—3/45 (6.7%)44/45 (97.8%)
Most frequent serious events
Most frequent serious events
EventTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
OrchitisInfections and infestations0/211/160/450/45
ContusionInjury, poisoning and procedural complications0/211/160/450/45
AppendicitisInfections and infestations0/210/162/450/45
Abdominal painGastrointestinal disorders0/210/160/451/45
Injection site erythemaGeneral disorders0/210/160/451/45
Injection site painGeneral disorders0/210/160/451/45
Injection site swellingGeneral disorders0/210/160/451/45
Foot fractureInjury, poisoning and procedural complications0/210/161/450/45
Upper limb fractureInjury, poisoning and procedural complications0/210/160/451/45
Most frequent other events
Showing 10 of 114
Most frequent other events
EventTwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcg
HeadacheNervous system disorders12/214/1618/4523/45
Upper respiratory tract infectionInfections and infestations11/215/1625/4523/45
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/210/1610/455/45
Abdominal painGastrointestinal disorders3/213/165/457/45
SunburnInjury, poisoning and procedural complications2/213/161/451/45
ArthralgiaMusculoskeletal and connective tissue disorders1/213/162/451/45
NauseaGastrointestinal disorders0/211/168/451/45
VomitingGastrointestinal disorders3/212/163/453/45
InfluenzaInfections and infestations2/212/166/454/45
Viral infectionInfections and infestations0/210/165/456/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)TwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcgTotal
Mean10.19 ± 1.4410.69 ± 0.9510.31 ± 1.2410.31 ± 1.2910.34 ± 1.25
Sex: Female, Male
Sex: Female, Male(Participants)TwinrixInitial Formulation rLP2086 20 mcgInitial Formulation rLP2086 60 mcgInitial Formulation rLP2086 200 mcgTotal
Female109222869
Male117231758
08

Study locations

9 sites
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Royal Children's Hospital
    Herston, Queensland 4006, Australia
  • Princess Margaret Hospital for Children
    Subiaco, Western Australia 6008, Australia
  • Sir Albert Sakzewski Virus Research Centre (SASVRC)
    Herston, QLD 4006, Australia
  • Women's & Children's Hospital
    North Adelaide, SA 5006, Australia
  • The Telethon Institute for Child Health Research
    Subiaco, WA 6008, Australia
  • National Centre for Immunisation
    Westmead, NSW 2145, Australia
  • Department of Paediatrics and Child Health
    Woden, ACT 2606, Australia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2006
First posted
Oct 13, 2006
Start
Nov 2006
Primary completionActual
Jan 2008
CompletionActual
Feb 2008
Results first posted
Nov 21, 2014
Last update
Nov 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00387725
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 13, 2006
Start date
Nov 2006
Primary completion
Jan 2008
Completion
Feb 2008
Results posted
Nov 21, 2014
Last update
Nov 21, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion